MindWalk Announces Rebranding and NASDAQ Ticker Change to "HYFT"

ImmunoPrecise Antibodies Ltd. has rebranded as MindWalk and changed its Nasdaq ticker symbol to HYFT, reflecting its evolution into a Bio-Native AI platform business. The company aims to accelerate discovery by integrating data across formats and disciplines, making biological diversity computable. MindWalk is expanding beyond wet-lab services to commercialize an intelligence-platform model, offering DaaS and SaaS offerings, enhancing asset generation, and enabling large-scale partnerships.

ImmunoPrecise Antibodies Ltd. has rebranded as MindWalk and changed its Nasdaq ticker symbol to HYFT, signaling a significant shift in its business focus. The company, now known as MindWalk, is evolving into a Bio-Native AI platform business, aiming to accelerate discovery by integrating data across various formats and disciplines. This transformation reflects MindWalk's commitment to making biological diversity computable and enhancing asset generation.

The rebranding comes with an expansion beyond traditional wet-lab services. MindWalk is now commercializing an intelligence-platform model, offering Data as a Service (DaaS) and Software as a Service (SaaS) offerings. These new services aim to streamline data analysis and decision-making processes, enabling large-scale partnerships and fostering innovation in the life sciences sector.

MindWalk's CEO and co-founder, Dr. Michelle Longmire, stated, "MindWalk is more than just technology – it’s a catalyst to unleash greater human potential in life sciences. It frees teams from the bottlenecks of legacy systems, accelerates trials, reduces costs, and ultimately helps bring medicines to patients faster."

The company's new platform, Agent Studio, exemplifies this commitment. Agent Studio is a no-code agent-builder that enables clinical teams to quickly custom-configure AI agents, driving unprecedented efficiencies across the clinical development life cycle [1]. This platform, designed to remove bottlenecks and streamline trial processes, aligns with MindWalk's vision of accelerating the discovery and development of effective therapies.

MindWalk's move into the Bio-Native AI space is part of a broader trend in the life sciences industry. Companies are increasingly leveraging AI and machine learning to enhance drug discovery, improve clinical trials, and optimize healthcare outcomes. By integrating data across formats and disciplines, MindWalk aims to provide a more comprehensive and efficient approach to biological research.

As MindWalk expands its offerings, it will be crucial to monitor its performance and assess the market's reception to its new services. The company's ability to attract large-scale partnerships and successfully commercialize its intelligence-platform model will be key indicators of its success.

References:
[1] https://www.morningstar.com/news/business-wire/20250903949263/medable-launches-the-industrys-first-agentic-ai-platform-and-cra-agent-removes-bottlenecks-in-clinical-development